WPHM Winston Pharmaceuticals Inc (CE)

CUSIP No. 975657107 Page 2 of 5 Pages

--------------------------------------------------------------------------------
1. Names of Reporting Persons
 I.R.S. Identification Nos. of above persons (Entities Only)

 Phillip Frost, M.D.
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
 (a) |_|
 (b) |_|
--------------------------------------------------------------------------------
3. SEC use only


--------------------------------------------------------------------------------
4. Source of Funds (See Instructions)

 N/A
--------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
 2(d) or 2(e) |_|

--------------------------------------------------------------------------------
6. Citizenship or Place of Origin

 United States
--------------------------------------------------------------------------------
Number of 7. Sole Voting Power -0-
Shares ------------------------------------------------------------
Beneficially 8. Shared Voting Power 26,574,659 (1)
Owned by ------------------------------------------------------------
Each Reporting 9. Sole Dispositive Power -0-
Person ------------------------------------------------------------
With 10. Shared Dispositive Power 26,574,659 (1)
--------------------------------------------------------------------------------
11. Aggregate Amount Owned by Each Reporting Person

 26,574,659 (1)
--------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
 Instructions) |_|

--------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)

 30.8%
--------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions)

 IN
--------------------------------------------------------------------------------

(1) Includes 17,794,862 shares of common stock and 8,779,797 warrants to
purchase common stock which are held by Frost Gamma Investments Trust of which
the reporting person is the trustee.

CUSIP No. 975657107 Page 3 of 5 Pages

--------------------------------------------------------------------------------
1. Names of Reporting Persons
 I.R.S. Identification Nos. of above persons (Entities Only)

 Frost Gamma Investments Trust
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
 (a) |X|
 (b) |_|
--------------------------------------------------------------------------------
3. SEC use only


--------------------------------------------------------------------------------
4. Source of Funds (See Instructions)

 WC
--------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items
 2(d) or 2(e) |_|

--------------------------------------------------------------------------------
6. Citizenship or Place of Origin

 Florida
--------------------------------------------------------------------------------
Number of 7. Sole Voting Power -0-
Shares ------------------------------------------------------------
Beneficially 8. Shared Voting Power 26,574,659 (1)
Owned by ------------------------------------------------------------
Each Reporting 9. Sole Dispositive Power -0-
Person ------------------------------------------------------------
With 10. Shared Dispositive Power 26,574,659 (1)
--------------------------------------------------------------------------------
11. Aggregate Amount Owned by Each Reporting Person

 26,574,659 (1)
--------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See
 Instructions) |_|

--------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)

 30.8%
--------------------------------------------------------------------------------
14. Type of Reporting Person (See Instructions)

 OO
--------------------------------------------------------------------------------
(1) Includes 17,794,862 shares of common stock and 8,779,797 warrants to
purchase shares of common stock.

CUSIP No. 975657107 Page 4 of 5 Pages

 AMENDMENT No.3 TO SCHEDULE 13D

 This Amendment No. 3, dated February 22, 2010, to the statement on
Schedule 13D, dated March 21, 2007 (the Original Statement"), which was amended
by that certain Amendment No. 1, dated November 13, 2007 (the "First Amendment")
and by Amendment No. 2, dated October 6, 2008 (the "Second Amendment"), together
referred to herein as the "Statement", filed by the Reporting Persons relates to
the common stock, par value $.001 per share, of Winston Pharmaceuticals, Inc., a
Delaware corporation (the "Issuer"), and amends the Statement as set forth
below.

ITEM 1. Security and Issuer.

Item 1 is hereby deleted in its entirety and replaced with the following:

 This Schedule 13D is filed by Phillip Frost, M.D. and Frost Gamma
Investments Trust (the "Gamma Trust") (collectively, the "Reporting Persons")
with respect to shares of common stock, par value $.001 per share, of Winston
Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"). The address of the
Issuer's principal executive office is 100 North Fairway Drive, Suite 134,
Vernon Hills, IL 60061.

ITEM 2. Identity and Background.

Item 2 is hereby amended as follows:

 Dr. Frost's principal occupation is Chairman and Chief Executive Officer
of Opko Health, Inc. a Delaware corporation

ITEM 4. Purpose of Transaction

Item 4 is hereby amended to include the following:

 On September 24, 2009, each outstanding share of Winston Pharmaceuticals,
Inc. (the "Company") Series A Convertible Preferred Stock, par value $.001 per
share, and Series B Convertible Preferred Stock, par value $.001 per share,
automatically converted into 1,000 fully-paid, non-assessable shares of the
Company's common stock, par value $.001 per share ("Common Stock"). In addition,
in connection with such conversion, each outstanding warrant to purchase shares
of Series A Convertible Preferred Stock automatically converted into the right
to acquire 1,000 shares of Common Stock upon the exercise of such warrant, at an
exercise price of $0.39 per share of Common Stock.

CUSIP No. 975657107 Page 5 of 5 Pages

ITEM 5. Interest in Securities of the Issuer

Item 5 is hereby deleted in its entirety and replaced with the following:

 (a) - (b) Each of the Reporting Persons is the beneficial owner of
26,574,659 shares of Common Stock of the Issuer. Each of the Reporting Persons
is the beneficial owner of 30.83% of the Issuer's Common Stock. The percentage
of beneficial ownership is based upon 77,408,893 shares of Common Stock
outstanding as of November 13, 2009.

 (c) On February 12, 2010, Pharmaceutical Financial Syndicate, LLC
("PFS") executed a letter of intent with Frost Gamma Investments Trust (the
Reporting Persons), Subbarao Uppaluri, a director of the Company, Steven D.
Rubin, and Jane Hsiao, Ph.D. (collectively, the "Frost Group"), to acquire 100%
of the Company's capital stock (the "Acquisition") beneficially owned by all of
the members of the Frost Group consisting of an aggregate of 18,399,271
outstanding shares of common stock and warrants to purchase an aggregate of
8,958,975 shares of common stock (collectively, the "Acquired Securities"). Upon
completion of the Acquisition PFS would be the beneficial owner of all of the
Acquired Securities and the reporting persons would no longer own an interest in
the Company.

ITEM 6. Contracts, Arrangements, Understandings or Relationships with Respect to
 Securities of the Issuer

 See Item 5(c).

ITEM 7. Material to be filed as Exhibits

 Letter of Intent Between Pharmaceutical Financial Syndicate, LLC,
Frost Gamma Investments Trust, Subbarao Uppaluri, Steven D. Rubin and Jane
Hsiao, Ph.D.

 [The remainder of this page is left blank intentionally.]